Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine
- PMID: 32914727
- DOI: 10.2174/1871530320666200910105612
Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine
Abstract
Berberine (BBR) is a botanic alkaloid extracted from Coptis chinensis (Huanglian), which has various properties, compassing anti-hyperglycemia, anti-obesity, anti-inflammation, and improves insulin resistance, etc. Several researches have confirmed that BBR has effective actions in treating glycolipid metabolic abnormalities. BBR is also beneficial in regulating intestinal flora. Metabolic diseases are strongly associated with metabolic disorders, which are growing in the population and dramatically impacting human health, which also have been considered as a leading cause of diseases and death globally. This review is to evaluate the metabolic properties of BBR, and its potential application to the treatment of metabolic diseases by its effective actions on metabolic disorders.
Keywords: Berberine; chronic inflammatory; insulin resistance; intestinal flora.; metabolic disorders; nonalcoholic fatty liver disease; type 2 diabetes.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders.Pharmacol Ther. 2020 May;209:107496. doi: 10.1016/j.pharmthera.2020.107496. Epub 2020 Jan 27. Pharmacol Ther. 2020. PMID: 32001311 Review.
-
Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence.Biomed Pharmacother. 2021 Jan;133:110984. doi: 10.1016/j.biopha.2020.110984. Epub 2020 Nov 10. Biomed Pharmacother. 2021. PMID: 33186794 Review.
-
Effect and mechanism of berberine against polycystic ovary syndrome.Biomed Pharmacother. 2021 Jun;138:111468. doi: 10.1016/j.biopha.2021.111468. Epub 2021 Mar 16. Biomed Pharmacother. 2021. PMID: 33740526 Review.
-
Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics.Theranostics. 2019 Mar 16;9(7):1923-1951. doi: 10.7150/thno.30787. eCollection 2019. Theranostics. 2019. PMID: 31037148 Free PMC article. Review.
-
Oxyberberine, an absorbed metabolite of berberine, possess superior hypoglycemic effect via regulating the PI3K/Akt and Nrf2 signaling pathways.Biomed Pharmacother. 2021 May;137:111312. doi: 10.1016/j.biopha.2021.111312. Epub 2021 Jan 30. Biomed Pharmacother. 2021. PMID: 33524788
Cited by
-
Exploring the protective effects of herbal monomers against diabetic retinopathy based on the regulation of autophagy and apoptosis: A review.Medicine (Baltimore). 2023 Oct 27;102(43):e35541. doi: 10.1097/MD.0000000000035541. Medicine (Baltimore). 2023. PMID: 37904448 Free PMC article. Review.
-
Research Progress on Neuroprotective Effects of Isoquinoline Alkaloids.Molecules. 2023 Jun 16;28(12):4797. doi: 10.3390/molecules28124797. Molecules. 2023. PMID: 37375352 Free PMC article. Review.
-
Anti-Neuroinflammatory Potential of Natural Products in the Treatment of Alzheimer's Disease.Molecules. 2023 Feb 3;28(3):1486. doi: 10.3390/molecules28031486. Molecules. 2023. PMID: 36771152 Free PMC article. Review.
-
Multi-target regulation of intestinal microbiota by berberine to improve type 2 diabetes mellitus.Front Endocrinol (Lausanne). 2022 Nov 18;13:1074348. doi: 10.3389/fendo.2022.1074348. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36465656 Free PMC article. Review.
-
Investigating the Mechanism of Rhizoma Coptidis-Eupatorium fortunei Medicine in the Treatment of Type 2 Diabetes Based on Network Pharmacology and Molecular Docking.Biomed Res Int. 2022 Nov 21;2022:7978258. doi: 10.1155/2022/7978258. eCollection 2022. Biomed Res Int. 2022. PMID: 36452059 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
